Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia
Hadas Lewinsky, … , Shirly Becker-Herman, Idit Shachar
Hadas Lewinsky, … , Shirly Becker-Herman, Idit Shachar
Published October 2, 2018
Citation Information: J Clin Invest. 2018;128(12):5465-5478. https://doi.org/10.1172/JCI96610.
View: Text | PDF
Research Article Immunology Oncology

CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia

  • Text
  • PDF
Abstract

Chronic lymphocytic leukemia (CLL) is characterized by clonal proliferation and progressive accumulation of mature B lymphocytes in the peripheral blood, lymphoid tissues, and bone marrow. CLL is characterized by profound immune defects leading to severe infectious complications. T cells are numerically, phenotypically, and functionally highly abnormal in CLL, with only limited ability to exert antitumor immune responses. Exhaustion of T cells has also been suggested to play an important role in antitumor responses. CLL-mediated T cell exhaustion is achieved by the aberrant expression of several inhibitory molecules on CLL cells and their microenvironment, prominently the programmed cell death ligand 1/programmed cell death 1 (PD-L1/PD-1) receptors. Previously, we showed that CD84, a member of the SLAM family of receptors, bridges between CLL cells and their microenvironment. In the current study, we followed CD84 regulation of T cell function. We showed that cell-cell interaction mediated through human and mouse CD84 upregulates PD-L1 expression on CLL cells and in their microenvironment and PD-1 expression on T cells. This resulted in suppression of T cell responses and activity in vitro and in vivo. Thus, our results demonstrate a role for CD84 in the regulation of immune checkpoints by leukemia cells and identify CD84 blockade as a therapeutic strategy to reverse tumor-induced immune suppression.

Authors

Hadas Lewinsky, Avital F. Barak, Victoria Huber, Matthias P. Kramer, Lihi Radomir, Lital Sever, Irit Orr, Vita Mirkin, Nili Dezorella, Mika Shapiro, Yosef Cohen, Lev Shvidel, Martina Seiffert, Yair Herishanu, Shirly Becker-Herman, Idit Shachar

×

Figure 5

Reduced abundance of exhausted CD8+ T cells in the CD84–/– environment.

Options: View larger image (or click on image) Download as PowerPoint
Reduced abundance of exhausted CD8+ T cells in the CD84–/– environment.
...
Eμ-TCL1 splenocytes (4 × 107) were injected i.v. into the tail vein of C57BL/6 WT or CD84–/– mice. (A–D) After 14 to 21 days, the mice were sacrificed, and expression of the exhaustion markers PD-1, LAG-3, CTLA-4, 2B4, and KLRG1 were determined on CD8+ T cells in (A) spleen (n = 6–11) histograms show representative results; (B) PB (n = 5–11); (C) the peritoneal cavity (n = 6–10); and (D) BM (n = 4–7). (E) After 14 to 21 days, the mice were sacrificed, and splenic cells were cultured for 24 hours with anti-CD3 and then with brefeldin A for the last 2 hours of culture. CD8+ T cells were then analyzed for IFN-γ, IL-2, GZMB, and LAMP-1 expression (n = 7–8). Dot plot show representative results of granzyme b expression. (F and G) BM cells (5 × 106) derived from 8-week-old Eμ-TCL1 mice or negative control littermates (WT) were injected into lethally irradiated C57BL/6 (WT) or CD84-deficient (CD84−/−) mice. After 6 months, the mice were euthanized, and the expression of PD-1 was determined on CD8+ T cells in the peritoneum (F) and spleen (G) (n = 3–4). *P < 0.05 (A–G), **P < 0.01 (A–E), ***P < 0.001 (A–D), and ****P < 0.0001 (A), 2-tailed t test. P = 0.3172 (NS), 2-tailed t test (E).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts